 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. NASDAQ: NEOS to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh 